Yang W#, Liu F#, Xu R#, Yang W#, He Y#, Liu Z#, Zhou F#, Heng F, Hou B, Zhang L, Chen L, Zhang F, Cai F, Xu H, Lin M, Liu M, Pan Y, Liu Y, Hu Z, Chen H, He Z, Ke Y. Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-World Data.,Ann Surg,277(1):e61-e69

Liu M#, Yang W#, Guo C#, Liu Z#, Li F, Liu A, Yang H, Shen L, Wu Q, Duan L, Wang H, Tian H, Shi C, Pan Y, Liu Y, Liu F, Weiss NS, Cai H, He Z*, Ke Y. Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.,J Clin Oncol,2024;42(14):1655-1664.

Liu F, Yang W, He Y, Yang W, Chen L, Xu R, Liu Z, Ke J, Hou B, Zhang L, Lin M, Liang L, Huang Y, Zhang L, Zhang F, Cai F, Xu H, Liu M, Pan Y, Liu Y, He Z, Ke Y. Surgical quality determines the long-term survival superiority of right over left thoracic esophagectomy for localized esophageal squamous cell carcinoma patients: a real-world multicenter study,Int J Surg,Int J Surg. 2024 Feb 1;110(2):675-683. doi: 10.1097/JS9.0000000000000897.

Liu F#, Yang W#, Yang W#, Xu R#, Chen L#, He Y#, Liu Z#, Zhou F#, Hou B, Zhang L, Zhang L, Zhang F, Cai F, Xu H, Lin M, Liu M, Pan Y, Liu Y, Hu Z, Chen H, He Z*, Ke Y*. Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer From a Real-world Multicenter Study,Ann Surg,277(4):e777-e784

He Y#, Pang Y#, Yang W#, Su Z, Wang Y, Lu Y, Jiang Y, Zhou Y, Han X, Song L, Wang L, Li Z, Lv X, Wang Y, Yao J, Liu X, Zhou X, He S, Zhang Y, Song L, Li J, Wang B, Ke Y, He Z*, Tang L*. Development of a prediction model for suicidal ideation in patients with advanced cancer: A multicenter, real-world, pan-cancer study in China,Cancer Med,13(12):e7439

Liang L#, Liu F#, Yang W#, Yang W#, Chen L#, He Y, Liu Z, Zhang L, Zhang F, Cai F, Xu H, Lin M, Liu M, Pan Y, Liu Y, Hu Z, Chen H, He Z*, Ke Y*. Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma.,Ann Surg Oncol,29(9):5626-5633

食管鳞癌根治术后患者预后预测模型构建方法及装置, 发明专利, 第3完成人, 国家知识产权局, 中国, 2024.7

一种老年肺癌患者术后短期死亡风险评估的方法及装置, 发明专利, 第5完成人, 国家知识产权局, 中国, 2024.1

基于多中心真实世界临床队列的胃癌预后预测与最优诊疗研究, 课题负责人, 2024.1.1～2026.12.31, 国家自然科学基金